Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: replaced MNT with ivMN

...

Expand
titlets.xpt (trial summary, study level parameters)
  • Assumption: Study can have more than one assay type
  • Assumption: ASSAYID value of ALL means it applies to all assays in the study
  • Replaced ivMN with ivMN - is this better?
  • BLEO & CPA - are positive controls, should this be included/where is this captured? — in results for the record / row?
  • Where is TK6 cell type?  is this test system (see below)
TRTMNTMNTMNTMNTMNTMNT

Row

STUDYID

ASSAYID

DOMAIN

TSSEQ

TSGRPID

TSPARMCD

TSPARM

TSVAL

TSVALNF

1123

ALL

TS1
GLPTYPGood Laboratory Practice TypeFDA
11123ALLTS1
STSTDTCStudy Start Date2007-12-30
13123ALLTS1
STITLEStudy TitleExample of a Crossover study in the Rat with 3 dose levels and 3 dosing periods
14123ALLTS1
SNDIGVERSEND Implementation Guide VersionTobacco IMPLEMENTATION GUIDE VERSION 1.0
15123

ALL

TS1
SNDCTVERSEND Controlled Terminology VersionSEND Terminology 2021-03-26
17123ALLTS1
SSPONSORSponsor OrganizationExample Sponsor Inc.
18123ALLTS1
SPREFIDSponsor's Study Reference ID
NOT APPLICABLE
19123ALLTS11TSTFNAMTest Facility NameExample Tox Lab Name
20123

ALL

TS11TSTFLOCTest Facility Location10 Somewhere Street, Montgomery, AL 10000
21123ALLTS11TFCNTRYTest Facility CountryUSA
24123ALLTS11STDIRStudy DirectorDr. R. Smith25123TS1Investigational Therapy or TreatmentDrug A
26123TS12TRTVTreatment VehicleSaline27123TS12TRTVDESCTreatment Vehicle Structured Description100.46 %(w/v) ISOTONIC SODIUM CHLORIDE SOLUTION {UNII VR5Y7PDT5W}28123ALLTS1
GLPFLGLP FlagY
29123ivMNTS1
ASTDAssay StandardOECD Test No. 487 
30123ivMNTS1
ASTDVAssay Standard Version2016-07-29
31123ivMNTS1
SSTYPStudy TypeGENOTOXICITY IN VITRO
32123ivMNTS1
SSSTYPStudy Sub TypeIn Vitro Micronucleus
33123ivMNTS1
SPECIESSpeciesHomo Sapiens
34123ivMNTS1
??Test System?TK6 Lymphoblastoid Suspension Cells
35123NRUTS1
ASTDAssay StandardNIH Publication No. 07-4519
36123NRUTS1
ASTDVAssay Standard Version2006-11
37123NRUTS1
SSTYPStudy Type

38123NRUTS1
SSSTYPStudy Sub TypeIn Vitro Neutral Red Uptake
39123NRUTS1
SPECIESSpeciesHomo Sapiens

40

123NRUTS1
??Test System??Normal Human Keratinocyte
Expand
titletx.xpt (trial sets)

Treatment Duration will be controlled?  During CT definition/reviews will need to decide appropriate Treatment duration values; For now, we just include good example values based on our experience

RowSTUDYIDASSAYIDDOMAINSETCDSETTXSEQTXPARMCDTXPARMTXVAL
1123MNTivMNTXA1

METACTMetabolic Activation  (should there be two parms? Presence, type)?+S9
2123MNTivMNTXA1

TRTDRTRGTreatment Duration target. (how do we show 3-6 hour range?  start/end, target and tolerance?, one text field not-analyzable)3

















TRTDRTOLTreatment Duration Tolerance







TRTDURUTreatment Duration Unit (this is for both TRTDURT, TRTDURTOL)H
3123MNTivMNTXA1

PRDCONCConcentration of product0
4123MNTivMNTXA1

PRDCONCUConcentration Unitug/ml
5123MNTivMNTXA1

ProductProduct Name
6123MNTivMNTXA1


Smoking Regime
7123MNTivMNTXA1


Smoke Fraction

123MNTivMNTXA2

METACTMetabolic Activation+S9

123MNTivMNTXA2

TRTDURTreatment DurationShort Term

123MNTivMNTXA2

PRDCONCConcentration of product1250

123MNTivMNTXA2

PRDCONCUConcentration Unitug/ml

123MNTivMNTXA2

ProductProduct Name

123MNTivMNTXA2


Smoking Regime

123MNTivMNTXA2


Smoke Fraction

123MNTivMNTX

B1



METACTMetabolic Activation-S9

123MNTivMNTX

B1



TRTDRTRGTreatment Duration target4







TRTDRTOLTreatment Duration Tolerance.25
??123MNTivMNTXB1

TRTDURUTreatment Duration Unit (this is for both TRTDURT, TRTDURTOL)H

123MNTivMNTX

B1



PRDCONCConcentration of product0

123MNTivMNTX

B1



PRDCONCUConcentration Unitug/ml

123MNTivMNTXB1

ProductProduct Name

123MNTivMNTXB1


Smoking Regime

123MNTivMNTXB1


Smoke Fraction

123MNTivMNTX

C1



METACTMetabolic Activation-S9

123MNTivMNTX

C1



TRTDURTreatment Duration24
??123MNTivMNTXC1

TRTDURUTreatment Duration UnitH

123MNTivMNTX

C1



PRDCONCConcentration of product0

123MNTivMNTX

C1



PRDCONCUConcentration Unitug/ml

123MNTivMNTX

C1



ProductProduct Name

123MNTivMNTXC1


Smoking Regime

123MNTivMNTX

C1




Smoke Fraction
Expand
titlegt.xpt (similar to LB)
RowSTUDYIDASSAYIDDOMAINTXCDGTSEQGTTESTCDGTTESTGTCELLEV
(cells evaluated)
GTORRESGTORRESUGTSTRESCGTSTRESNGTSTRESUGTDTCGTNOMDYGTELTMGTTPTREF
1123MNTivMNGTA21RICC
13415.7%15.715.7%2022-05-25


2123MNTivMNGTA22RCC
13413.0%13.013.0%2022-05-25


3123MNTivMNGTA23RPD
1347.9%7.97.9%2022-05-25


4123MNTivMNGTA24MNCELLSMicronucleated Cells326620Cells2020Cells2022-05-25


5123MNTivMNGTA25MNCELLSMicronucleated Cells219017Cells1717Cells2022-05-25


6123MNTivMNGTA26MNCELLSMicronucleated Cells275813Cells1313Cells2022-05-25


7123MNTivMNGTA27MNCELLSMicronucleated Cells271421Cells2121Cells2022-05-25


8123MNTivMNGTA28AVGRELAverage Relative MN Frequency
0.66%0.660.66%2022-05-25


9123MNTivMNGTA11RICC
1540%00%2022-05-25


10123MNTivMNGTA12RCC
1540%00%2022-05-25


11123MNTivMNGTA13RPD
1540%00%2022-05-25


12123MNTivMNGTA14MNCELLSMicronucleated Cells326615Cells1515Cells2022-05-25


13123MNTivMNGTA15MNCELLSMicronucleated Cells219013Cells1313Cells2022-05-25


14123MNTivMNGTA16MNCELLSMicronucleated Cells275817Cells1717Cells2022-05-25


15123MNTivMNGTA17MNCELLSMicronucleated Cells271412Cells1212Cells2022-05-25


16123MNTivMNGTA18AVGRELAverage Relative MN Frequency
0.57%0.570.57%2022-05-25










































































...